COLL - Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
2024-05-13 15:23:02 ET
Summary
- Collegium Pharmaceutical, Inc. stock fell 16% on Friday after Q1 results missed expectations and a CEO replacement was announced.
- Despite the negative reaction, there were some positive aspects in the results and guidance.
- An updated analysis around Collegium Pharmaceuticals is provided in the paragraphs below.
Today, we are putting Collegium Pharmaceutical, Inc. ( COLL ) in the spotlight. The stock of this small biopharma name fell some 16% on Friday after the company posted Q1 results that slightly missed both top and bottom-line expectations. The company also announced it was replacing its CEO. However, there were some positives from these results and disclosure. The sell-off might have some elements of a knee-jerk reaction. We take a more in-depth look at Friday's news items below....
Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'